Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM nejm.org Nawigacja wpisu ‘In regenerative medicine, the new organ is never rejected’ – EL PAÍS USA The German Network for Personalized Medicine to enhance patient care and translational research – Nature.com
